Willow Biosciences Inc (TSE:WLLW) has released an update.
Willow Biosciences Inc. has initiated a second collaboration with a global API manufacturer to develop an optimized enzyme for a high-volume pharmaceutical ingredient, aiming to enable mass production by 2025. This partnership, following a successful first program, seeks to create a sustainable and cost-effective manufacturing process for an ingredient with a market value over $1 billion.
For further insights into TSE:WLLW stock, check out TipRanks’ Stock Analysis page.
